News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ANSVQ revoked:
http://www.sec.gov/litigation/admin/2012/34-66436.pdf
10 month ANSVQ chart:
ANSVQ chart looking close to juice time... anyone adding this one down here? 4 month chart:
ANSV chart turned sour when she slipped below the 100DMA and parSAR sell signal showed up on June 23. ADX green dropped below red, Trix 3,3 went negative along with OBV drop below the 20MA around same date. Confimation to sell occured a few days later when PPO and MACD both dropped under the zero line.
Chart shows support at .17 and .18, and pps needs to hold there, or price could continue down to Nov 08' support at .06.
http://www.stockta.com/cgi-bin/analysis.pl?symb=ANSV&num1=1&cobrand=&mode=stock
Lastest ANSV news:
Anesiva Receives NASDAQ Delisting Staff Determination Letter
SOUTH SAN FRANCISCO, Calif., July 23 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) received, as previously disclosed on its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 2, 2009 and in its press release on April 1, 2009, a letter from the NASDAQ Stock Market LLC ("NASDAQ") on March 27, 2009, informing Anesiva that it was not in compliance with Marketplace Rule 4450(a)(3) (which has since been superseded by Rule 5450(b)(1)(A)) (the "Rule"), because Anesiva's stockholder's equity at December 31, 2008 was less than the minimum $10.0 million required for continued listing on The NASDAQ Global Market.
On July 17, 2009, Anesiva received a letter from NASDAQ notifying Anesiva that based on NASDAQ's further review of Anesiva and material submitted by Anesiva, Anesiva has failed to regain compliance with the Rule and that, therefore, NASDAQ has determined to delist the Company's securities from The NASDAQ Global Market.
Anesiva has requested a hearing before a NASDAQ Hearings Panel to appeal the determination to delist Anesiva's securities. Anesiva's securities will remain listed on The NASDAQ Global Market pending a decision by the Hearings Panel following the hearing.
About Anesiva
Anesiva seeks to be a leader in the development and commercialization of novel pharmaceutical products for pain management. The company's lead product candidate is Adlea, a novel small molecule formulation of capsaicin that is currently in development for the management of acute pain following orthopedic surgeries. Adlea has been shown in clinical trials to provide extended pain relief after only a single administration in multiple indications for site-specific, acute and chronic, moderate-to-severe pain.
In December 2008, Anesiva announced that a Phase 3 clinical trial of Adlea achieved its primary efficacy endpoint of reduced post-surgical pain versus placebo (p=0.03) following total knee arthroplasty (TKA) at four to 48 hours after surgery. The trial also met its key secondary endpoint with Adlea demonstrating a highly significant reduction in opioid medication consumption compared to placebo (p=0.005).
The Phase 3 TKA trial, known as ACTIVE-2, also showed that Adlea's safety profile of adverse events, wound healing, and wound sensory function were similar to placebo over the study duration.
ANSV nice chart and sector~ In starter today :)
|
Followers
|
11
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
518
|
|
Created
|
08/12/07
|
Type
|
Free
|
| Moderators | |||
